| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGCUUGCGGCCUGUGUCUAUGGUCGGGCCCUCUGCGUCCAGCUGCUCCG… | 1865 nt | 0.5201 |
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008] CIViC Summary for CDK4 Gene CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.
A study in humans demonstrated that the CDK4 was upregulated in the plasma of coronary artery disease patients and showed the highest predictive value for diagnosis with an area under the curve of 0.91 in receiver operating characteristic analysis [Abdallah et al. DOI:10.1007/s40291-022-00622-1].